MedTrace Logo

A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities

NCT02915224 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-06-28

No results posted yet for this study

Summary

This multicenter, single arm, non-interventional, observational study will evaluate the efficacy and safety of obinutuzumab in daily clinical practice in participants with chronic lymphocytic leukemia (CLL). The study will also assess cost of disease management. The total length of the study is 42 months.

Conditions

Interventions

DRUG

Chlorambucil

Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.

DRUG

Obinutuzumab

Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-23
Primary Completion
2021-06-08
Completion
2021-06-08

Countries

  • Greece

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02915224 on ClinicalTrials.gov